In this study, to identify potential therapeutic targets that are effective against KRAS-mutated NSCLC, we conducted a CRISPR-Cas9 knockout screen using a crRNA library and a drug screen using a custom library of compounds. Here, KRAS is linked to non-small cell lung carcinoma.